Corporate Access Event January 11 - 14, 2016
Meeting Schedule, January 11th – 14th San Francisco, CA
French Biotech Co.
CEO, CFO
VP Business Development Strategic Advisor Immuno-Oncology
Company Meeting Location: Sir Francis Drake Hotel Room # 450 P owell Street San Franc isco, CA
If questions should arise, please contact:
Andrew McDonald Mobile: Email: [email protected]
Angela Qian Mobile: Email: [email protected] -1
Corporate Access Event January 11 - 14, 2016
MEETINGS
Note: (*) indicates that this meeting time is double-booked.
Meeting Time Room Meeting With Note Type Monday, January 11, 2016 08:00-09:00 am Sir Francis Drake (450 1x1 Aquilo Capital Powell St), Room 530 Patrick Rivers 09:00-10:00 am Sir Francis Drake (450 1x1 Auriga Capital Powell St), Room 530 Glen Losev 10:00-11:00 am Hotel Nikko (222 Mason 1x1 Takeda St), 25th Floor, Bay Kiran Philip View Room 11:00-12:00 pm Sir Francis Drake (450 1x1 Granite Investment Partners LAST MINUTE Powell St), Room 530 Jeffrey Hoo CANCELLATION 12:00-1:00 pm Marriott Marquis (780 1x1 AbbVie Onsite Contact: Mission St), Salon 14 Niels Emmerich Tiffany Cincotta-Janzen, (847) 393-5723 01:30-02:00 pm Sir Francis Drake (450 1x1 Alpine BioVentures, GP LLC Powell St), Room 530 David Miller 03:00-03:30 pm Sir Francis Drake (450 1x1 Tara Capital Grp Powell St), Room 530 Dhesh Govender 04:00-05:00 pm Sir Francis Drake (450 1x1 EVOLUTION Life Science Partners Powell St), Room 530 Anton Gueth Tuesday, January 12, 2016 07:00-08:30 am* Breakfast Fierce Biotech Big Data Breakfast CEO will attend. 07:00-09:00 am* Breakfast BCG's Gene Editing Event will attend.
09:30-10:00 am Parc 55 San Francisco 1x1 Edison (55 Cryil Magnin St) Melissa Mayfield 10:30-11:30 am* Fairmont Hotel (950 1x1 Novartis Mason St) 11:00-11:30 am* Sir Francis Drake (450 1x1 Silicon Valley Bank Powell St), Room 530 Nooman Haque 11:30-12:00 pm Sir Francis Drake (450 1x1 Syncona Partners Powell St), Room 530 Tim Funnell 12:00-12:45 pm* Marriott Marquis (780 1x1 Roche Partnering/Oncology Mission St), Foothill G2 Scott Moorefield, Dr. Barbara Room (Atrium Level) Lueckel 12:00-01:00 pm* Clift Hotel (495 Geary 1x1 Cowen and Company, LLC -2
Corporate Access Event January 11 - 14, 2016
St) Chris Swindle 01:00-01:45 pm W Hotel San Francisco 1x1 Pfizer (181 Third Street) 02:15-03:00 pm Sir Francis Drake (450 1x1 Jefferies Powell St), Room 530 Biren Amin 03:00-04:00 pm* Sir Francis Drake (450 1x1 Mossrock Powell St), Room 530 Thomas Malley 03:15-06:30 pm* Hilton Union Square Lecture Dr. Carl June's CRISPR/Cas9 (333 O'Farrell Street) Lecture 04:00-05:00 pm* TBD (per Petra) 1x1 ViroMed Co. Sheila Yi 04:30-05:00 pm* Sir Francis Drake (450 1x1 BAML Powell St), Room 530 Sara Blum 05:00-06:00 pm* Carlton Hotel (1075 1x1 Recordati Sutter St) Pier Paolo Ferlenga 05:30-06:00 pm* Sir Francis Drake (450 1x1 Lake Street Powell St), Room 530 Bruce Jackson Wednesday, January 13, 2016 06:30-07:30 am* ANZU at Hotel Nikko 1x1 NeoChord (222 Mason St) David Chung 07:00-08:00 am* Sir Francis Drake (450 1x1 Hillhouse Capital Group Powell St), Room 530 JQ Li 08:00-08:30 am Sir Francis Drake (450 1x1 Piper Jaffray Powell St), Room 530 Ted Tenthoff 08:30-09:00 am Sir Francis Drake (450 1x1 BMO Powell St), Room 530 Svetlana Makhni 09:00-10:00 am Sir Francis Drake (450 1x1 venBio Powell St), Room 530 Andy Washkowitz 10:00-11:00 am Sir Francis Drake (450 1x1 DAFNA Capital Management Powell St), Room 530 Nathan Fischel 11:00-12:00 pm Sir Francis Drake (450 1x1 LoneStar Heart, Inc. Powell St), Room 530 Frank Ahmann and Olav Bergheim 12:00-01:00 pm Sir Francis Drake (450 1x1 J.P. Morgan Powell St), Room 530 Cailin McGurk 01:00-01:30 pm Sir Francis Drake (450 1x1 Sphera Fund Powell St), Room 530 Hagai Schor 01:30-02:00 pm Sir Francis Drake (450 1x1 Ridgeback Capital Powell St), Room 530 Matt Mezvinsky 02:00-02:30 pm Sir Francis Drake (450 1x1 Juventas Therapeutics, Inc. Powell St), Room 530 Rahul Aras 03:00-04:00 pm* Sir Francis Drake (450 1x1 Wells Fargo Securities
-3
Corporate Access Event January 11 - 14, 2016
Powell St), Room 530 Marisa Frackman 03:00-04:00 pm* Sir Francis Drake (450 1x1 RS Investments Powell St), Room 530 Christopher Clark 04:00-04:30 pm* Sir Francis Drake (450 1x1 Chardan Capital Powell St), Room 530 Gbola Amusa 04:00-04:45 pm* TBD 1x1 UBS Ross Hammerman 04:30-05:00 pm* Sir Francis Drake (450 1x1 Great Point Partners, LLC Powell St), Room 902 Brett Erkman 06:00-07:00 pm* Sir Francis Drake (450 1x1 Ono Pharma Powell St), Room 530 Toichi Takino 06:00-07:00 pm* Four Seasons Hotel 1x1 Cantor Fitzgerald (757 Market St) Veet Misra
Thursday, January 14, 2016 08:30-09:15 am Sir Francis Drake (450 1x1 TxCell S.A. Powell St) Miguel Forte 10:00-11:00 am Hilton Union Square 1x1 Baxalta (333 O’Farrell Street) Karla Valentin and Stefan Krauss
-4
Corporate Access Event January 11 - 14, 2016
BACKGROUNDS FOR MEETINGS
AQUILO CAPITAL MANAGEMENT, LLC Patrick Rivers, Buy Side Analyst 415-635-0141
Rivers is an analyst at Aquilo Capital Management, LLC. He joined the firm in June 2014. Previously, Rivers was associated with Sutro Biopharma, Exelixis and Xoma. He received a BS in Chemical Engineering at UCLA and is an MBA candidate at UC Berkeley’s Haas School of Business.
Aquilo Capital Management, LLC invests in global biotechnology stocks across all market capitalizations. The firm employs: (a) fundamental; (b) technical; and, (c) charting analysis. Aquilo Capital meets with management. The firm relies on a combination of in-house analysis and sell-side research. Aquilo Capital seeks long only approach to select stocks.
AURIGA CAPITAL MANAGEMENT, LLC Glen Losev 646-998-6474 [email protected]
Losev is a director and a senior analyst at Auriga Capital Management, LLC. Previously, he was a senior analyst at WallachBeth Capital, LLC (August 2012 - July 2013). Prior to that, Losev was an analyst at Auriga USA, LLC (August 2011-July 2012). Before that, he was an associate at The Griswold Company, Inc. Prior to that, Losev was a research associate at CitiGroup Global Markets, Inc (October 2006-June 2008). Before that, he was an analyst at Oppenheimer & Company, Inc. (October 1999-October 2006). Prior to that, Losev was an analyst at SG Pacific Asset Management (September 1996-August 1999). Losev received a BBA in Finance from Lubin School of Business at Pace University and a BA in Sociology from New York University (NYU).
Auriga Capital Management, LLC invests in U.S. stocks across all market capitalizations in healthcare and technology sectors. The firm employs sector specific long/short strategy to pick the stocks for its portfolios.
Top 10 Holdings (USD, mm) Company Value Value Change % Port Novavax, Inc. 2.16 2.16 9.46% Heron Therapeutics, Inc. 1.50 -4.04 6.57% Aerie Pharmaceuticals, Inc. 1.40 1.40 6.12% Cerulean Pharma, Inc. 1.36 0.35 5.96% Stemline Therapeutics, Inc. 1.22 0.80 5.35% Juno Therapeutics, Inc. 1.22 1.22 5.32% -5
Corporate Access Event January 11 - 14, 2016
Colucid Pharmaceuticals, Inc. 1.08 1.08 4.71% Sunesis Pharmaceuticals, Inc. 1.02 1.02 4.48% Humana, Inc. 0.96 0.96 4.18% Xoma Corp. 0.89 0.46 3.89%
GRANITE INVESTMENT PARTNERS, LLC – LAST MINUTE CANCELLATION Jeffrey “Jeff” Hoo, Portfolio Manager 310-341-7140 [email protected]
Hoo is a principal, portfolio manager and an analyst at Granite Investment Partners, LLC. He joined the firm in April 2011. Previously, Hoo was a principal, portfolio manager, and a senior analyst at Transamerica Investment Management, LLC (August 2005 - March 2011). Prior to that, he was a principal and a portfolio manager at Westcap Investors, LLC (June 1997 - August 2005). Before that, Hoo was a finance manager at Sony Pictures Entertainment and an auditor at KPMG Peat Marwick. He received a BA from Duke University ('90) and an MBA from the University of California, Los Angeles (UCLA) ('98).
Granite Investment Partners, LLC (GIP) invests in U.S. growth and value stocks across all market capitalizations and sectors. The firm use fundamental analysis seeking stocks with superior business models exhibiting catalysts for positive change, which can result in rapid growth in earnings and revenue and discretionary free cash flow. Significant emphasis is placed on prudent and visionary managements with past records of success that act in the best interest of shareholders.
Top 10 Holdings (USD, mm) Value Company Value % Port Change Bank of the Ozarks Inc 7.09 0.88 0.89% ISHARES TR RUSSELL 2000 INDEX FUND 6.08 0.68 0.76% ABIOMED, Inc. 6.06 <.01 0.76% Callidus Software Inc. 5.93 0.26 0.74% Monro Muffler Brake, Inc. 5.73 0.92 0.72% The Ultimate Software Group, Inc. 5.65 -0.52 0.71% Tyler Technologies, Inc. 5.15 0.69 0.65% Pool Corporation 5.03 0.00 0.63% Stamps.com Inc. 5.02 -0.41 0.63% Clovis Oncology, Inc. 4.94 0.41 0.62%
ALPINE BIOVENTURES, LLC David Mille, Portfolio Manager -6
Corporate Access Event January 11 - 14, 2016
206-441-5064 [email protected]
Miller is a portfolio manager and proxy contact at Alpine BioVentures, LLC. He joined the firm in August 2013. Previously, Miller was the co-founder, president, analyst and CEO of Biotechnology Stock Research, LLC. Prior to that, he was a co-founder of entrepreneurs workshop course at University of Washington, Bothell (2001 - 2010). Before that, Miller worked for Seattle Campaign (November 2008 - August 2009). Prior to that, he was an adjunct professor at University of Washington, Bothell (2002 - 2003). Before that, Miller was the CEO at Versidata (1991 - 1998). He received a BA in Communications from Western Washington University ('90).
Alpine BioVentures, LLC invests in U.S. micro- to mid- capitalization stocks across biotechnology sector. . The firm employs a long/short strategy. Alpine BioVentures conducts internal analysis and uses bulge bracket and independent sell-side research. The firm either meets or speaks on the telephone with management as part of the investment process. Alpine BioVentures is willing to travel.
TARA IMMUNO-ONCOLOGY LLC Deshan (Desh) Govender
Before Mr. Govender founded Tara Immuno-Oncology in 2014, he served as director biotech and life sciences at Iroquois Capital Management. Earlier in his career he was director of the healthcare practice at Kingsbrook Partners. He holds degrees in molecular biology and biochemistry from Wesleyan University, as well as a master’s degree in biophysics and chemistry from the WM Keck Center for Molecular Electronics at Syracuse University.
Tara I-O is a private biopharmaceutical company formed in 2014 to advance novel immuno-oncology assets. Tara I-O has offices in New York, NY, and San Diego, CA. The company is utilizing its biotechnology drug development and business expertise to advance therapies toward registration and commercialization. Management has over 25 years of development experience with a proven track record of drug approvals.
EVOLUTION LIFE SCIENCE PARTNERS Anton Gueth
Mr. Gueth is a senior leader with nearly 30 years of experience in the healthcare industry in general management, financial management, M&A advisory services, corporate/business development, alliance development and sales and marketing. He has held management roles in Europe, the Middle East, Africa and the United States. He has proven results in income growth, large-scale deal structuring and general management. He is experienced with restructuring of sales and marketing organizations, strategic planning for geographic business units and corporate alliances, and Controlling and Treasury functions. He holds a degree in agricultural economics from Justus Liebig -7
Corporate Access Event January 11 - 14, 2016
University Giessen, and an MPA in public affairs, finance and economics from Indiana University Bloomington.
EVOLUTION Life Science Partners is an investment bank focused on the needs of life sciences and healthcare companies. They assist companies throughout their life cycle, including capital raising, licensing/partnering, and M&A. The firm’s work covers the large pharma, biotechnology, medical device, and molecular diagnostic sectors. The firm was formed in 2014 by experienced investment bankers, formerly with firms such as Lehman Brothers, Bear Stearns, Eli Lilly, GlaxoSmithKline, Bain & Company and Burrill Securities. The Firm’s Chairman, Fred Frank, is considered to be the first life sciences specialist in investment banking. He founded the biotechnology practice at Lehman Brothers. The senior bankers at EVOLUTION have an average of 25 Years of investment banking and industry experience, executing hundreds of M&A, partnering and capital raising engagements, with an aggregate deal value in excess of $125 Billion.
SILICON VALLEY BANK Nooman Haque
Nooman Haque is the Director of Healthcare & Life Sciences with Silicon Valley Bank’s UK Branch. He leads a team dedicated to supporting early, growth-stage and established businesses in all sectors of life sciences. Nooman is responsible for developing new relationships, identifying lending opportunities and working with the global life sciences team to support companies with all aspects of their business. He is actively involved within the sector, sitting on the BIA’s Finance and Tax Committee and is a frequent participant on panel and seminars. Nooman joined Silicon Valley Bank from a venture capital firm in London and previously ran a sovereign wealth fund in Saudi Arabia largely focused on healthcare. His background includes strategic and financial advisory, debt and equity structuring and risk management. Nooman has a Bsc in psychology and Msc in economics, both from the University of London, and an MBA (finance) from Imperial College. He is a member of the British Psychological Society and the Royal Economic Society.
SYNCONA PARTNERS Tim Funnell
Tim is a Partner of Syncona Partners LLP. Previously, he was a Consultant with the Boston Consulting Group where he focused on Healthcare projects, working with Pharma clients and a Global Health organisation. Tim holds a DPhil in Pharmacology from Oxford University and a MA in Natural Sciences from Cambridge University.
Syncona is an evergreen healthcare investment company that identifies and takes an active role in developing technologies to deliver transformative healthcare products. The Company was founded in October 2012 by the Wellcome Trust and all profits from the Syncona Group’s activities will be -8
Corporate Access Event January 11 - 14, 2016
recycled to support the charitable mission of the Trust. The Company focuses on technologies with the potential to significantly impact patients and the delivery of healthcare in the future and its investments to date include companies focused on gene therapy, cell therapy and patient stratification technologies.
COWEN & CO Chris Swindle [email protected]
Mr. Swindle is a Managing Director in the Health Care Investment Banking Group focusing on Biotechnology and Specialty Pharmaceuticals. Mr. Swindle joined Cowen from Wedbush Pacific Growth Life Sciences where he was Managing Director and Head of Health Care Investment Banking. Previously, he was a Managing Director at Pacific Growth Equities focused exclusively on emerging and specialty pharmaceuticals banking efforts. Prior to that role, Mr. Swindle was at Jefferies & Company, Inc. and Leucadia National Corporation. Mr. Swindle holds a B.A. from the University of California, Berkeley.
Cowen Group, Inc. is a leading diversified financial services firm providing alternative investment management, investment banking, research, and sales and trading services through its business units, Ramius and Cowen and Company. Its alternative investment management products include hedge funds, fund of funds, real estate funds, healthcare royalty funds, cash management and commodity trading funds, offered primarily under the Ramius name. Cowen and Company offers industry focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Founded in 1918, the firm is headquartered in New York and has offices located in major financial centers around the world.
JEFFERIES, LLC. Biren Amin, Analyst 212-284-8162 [email protected]
Amin is a senior research analyst at Jefferies, LLC. He joined the firm in June 2011. Previously, Amin was an analyst at WJB Capital Group (February 2010-June 2011). Prior to that, he was into biotechnology equity research at FTN Equity Capital (July 2009-February 2010). Before that, Amin was a principal at T-Rx Advisers, LLC (March 2009-July 2009). Prior to that, he was a senior vice president and biotechnology analyst at Stanford Group (November 2005-February 2009). Before that, Amin was an associate analyst at Prudential Equity Group (2004-2005). Prior to that, he was a senior manager, competitive intelligence at Aventis Pharmaceuticals (January 1999-January 2004). Amin received a BS in Pharmacy from the University of the Sciences in Philadelphia, an MS in Pharmacy from Long Island University, and an MBA from the Stern School of Business at New York University (NYU).
-9
Corporate Access Event January 11 - 14, 2016
Stocks Covered AAVL, ACRX, ADXS, ALKS, AMPE, ANTH, AQXP, BLCM, CLDX, CLLS, DYAX, EXEL, FWP, GLYC, GTXI, HRTX, IMDZ, KITE, LBIO, MDCO, MDVN, MRTX, NKTR, NLNK, ONTY, REGN, STML, TRVN, VSTM, XENE, XOMA
MOSSROCK CAPITAL, LLC Thomas “Tom” Malley, CFA 303-808-4745 [email protected]
Malley is a president and portfolio manager at Mossrock Capital LLC. He joined the firm in 2007. Malley is also on the board of directors at Project C.U.R.E., Puma Biotechnology, Synageva BioPharma Corp, St. Anthony Health Foundation, and he is also on the board of advisors at Coachman Energy. Previously, Malley was on the board of directors at Craig Hospital (March 2007 - March 2013). Prior to that, he was on the bord of advisors at Caddis Capital (2008 2012). Before that, Malley was on the board of directors at CHI Colorado Foundation (2006 October 2011). Prior to that, he was a member of Keiretsu Forum Denver/Rockies (2007 December 2009). Before that, Malley was on the board of directors at Cougar Biotechnology (2007 2009). Prior to that, he was on the board of directors at St. Anthony's Medical Center (2004 2009). Before that, Malley was a portfolio manager at Janus Capital Group (April 1991 May 2007). He received a degree in Biology from Stanford university (’91).
Mossrock Capital, LLC invests in U.S. growth stocks across all market capitalizations and sectors.
BANK OF AMERICA SECURITIES-MERRILL LYNCH Sara Blum 646-855-5000 [email protected]
Blum is a equity research analyst at Bank of America Securities-Merrill Lynch (U.S.) (Research). Before that, she was a treasury analyst at Bank of America Merrill Lynch. Prior to that, Blum was a Intern at Bloomberg Tradebook She attended Northwestern University.
LAKE STREET CAPITAL MARKETS Bruce Jackson 612-326-9536 [email protected]
Bruce is a senior healthcare research analyst with more than twenty years of experience both on and off Wall Street. He focuses on companies poised to benefit from changes in the healthcare system -10
Corporate Access Event January 11 - 14, 2016
and the drive for better patient outcomes at lower cost. In May, 2011, Bruce received an FT/StarMine Analyst Award for being the Number 1 stock picker in Health Care Equipment and Supplies and was named a Wall Street Journal All-Star for stock picking in Health Equipment & Supplies. Prior to becoming a Wall Street analyst, he served with Abbott Laboratories as a Project Manager in the Hospital Products Division, and as a Market Planner in the Abbott Diagnostics Division. Bruce began his Wall Street career at Vector Securities and has held senior analyst positions at Wachovia, RBC, Morgan Joseph TriArtisan, and Northland Securities. Bruce received a BA degree from University of Wisconsin and an MBA in General Management from the Johnson Graduate School of Management at Cornell University.
Stocks Covered AST, AXGN, BEAT, CYAD, EXAS, IART, MDXG, STRM, TRXC
HILLHOUSE CAPITAL GROUP JQ Li
Hillhouse Capital Group (“Hillhouse”) is a leading investment management firm founded by Mr. Zhang Lei in 2005. We manage over US$18bn of assets as of Dec 2014. We manage capital for institutional clients such as university endowments, foundations, sovereign wealth funds, pensions and family offices.
Hillhouse is a long-term fundamental equity investor with a global mandate. Independent, fundamental and proprietary research is key to our investment process. Our team focuses on the consumer, TMT, industrials and healthcare sectors and invests in companies across all equity stages.
PIPER JAFFRAY & CO Edward “Ted” Tenthoff 212-284-9403 [email protected]
Tenthoff is a managing director and a senior analyst at Piper Jaffray & Co. (U.S.). He joined the firm in May 2003. Previously, Tenthoff was associated with ThinkEquity Partners (August 2002-May 2003). Prior to that, he was affiliated with Robertson Stephens Inc (September 1998-August 2002). Before that, Tenthoff was associated with Lehman Brothers (July 1997-March 1998). Prior to that, he was affiliated with Rodman & Renshaw Inc (April 1997-July 1997). Tenthoff received a Bachelor's in International Relations from the University of Pennsylvania.
Stocks Covered ALNY, ANTH, ARNA, ARRY, ARWR, ATHX, CBAY, CYAD, ECYT, EXEL, GNCA, IDRA, MDGN WS, MSTX, NVAX, OMED, ONCYF, ONVO, OSIR, REGN, SGEN, SRPT, VRTX, VTAE, XLRN, XOMA -11
Corporate Access Event January 11 - 14, 2016
BMO CAPITAL MARKETS Svetlana Ni Makhni
Before joining BMO as vice president in 2015, Ms. Makhni was senior vice president of business development at NLabs. Prior to that, she was an associate at Goldman Sachs in the healthcare investment banking group. Earlier in her career, she was a vice president at Westbrook Partners and an analyst at the Blackstone Group. She holds a degree in finance and accounting from the Wharton School at the University of Pennsylvania and an MBA from Harvard Business School.
BMO Capital Markets is a leading, full-service North American financial services provider operating in 16 North American offices and 29 worldwide, offering corporate, institutional and government clients access to a complete range of investment and corporate banking products and services.
VENBIO Andy Washkowitz 212-937-4970
Prior to joining venBio in early 2015, Mr. Washkowitz was a biotechnology analyst with Stifel in New York. He holds a degree in biology from Harvard University, and several degrees, including a Ph.D. in biological sciences from Columbia University. venBio is a next-generation investment firm, partnering with life science leaders to invest in novel medicines and game changing technologies in the advancement of health care. VenBio was established with the intention of creating and implementing a new model of life sciences investing. Fundamentally, venBio believes that integrating and aligning all key stakeholders interest is critical to long term success. The firm’s investment teams, comprised of industry experts, partner with and invest in emerging biotechnology, life sciences and specialty pharmaceutical companies globally. VenBio manages both a long/short equity hedge fund along with a venture capital fund with is back by leading life sciences companies and qualified financial investors.
DAFNA CAPITAL MANAGEMENT, LLC Nathan Fischel, CFA [email protected]
Fischel is a founder, CEO, chief compliance officer, analyst and portfolio manager of DAFNA Capital Management, LLC. He founded the firm in January, 1999. Previously, Fischel worked as a director of molecular hematology, attending physician at Cedars-Sinai Medical Center (1988 - 2009). Prior to that, he was a professor at University of California, Los Angeles (UCLA) School of Medicine (1988 - 2009). Before that, Fischel was a co-founder, director and chief scientific officer at gene/Networks -12
Corporate Access Event January 11 - 14, 2016
(1994 - 1997). He received a MD ('83) and a Postgraduate in Molecular Genetics from Technion - Israel Institute of Technology ('87).
DAFNA Capital Management, LLC invests in U.S. healthcare stocks across all market capitalizations in all sectors. The firm seeks long/short approach for selection of stocks.
Top 10 Holdings (USD, mm) Value Company Value % Port Change AtriCure, Inc. 10.69 -1.33 9.93% Anavex Life Sciences Corporation 6.77 0.00 6.28% Abbvie, Inc. 6.34 0.00 5.89% NxStage Medical, Inc. 5.78 0.00 5.37% ZS Pharma, Inc. 4.35 -0.06 4.04% Achillion Pharmaceuticals, Inc. 3.32 0.00 3.08% BioCryst Pharmaceuticals, Inc. 2.95 0.42 2.74% Aerie Pharmaceuticals, Inc. 2.94 0.16 2.73% BioTelemetry, Inc. 2.88 0.00 2.68% Insulet Corporation 2.75 0.00 2.55%
LONE STAR HEART Olav Bergheim
Olav B. Bergheim has more than 30 years of experience in creating and managing life science companies. Mr. Bergheim’s vast experience includes almost 20 years in general management at Baxter Healthcare where he was the Corporate Vice President and President of the $700 million Cardiovascular Group (now Edwards Lifesciences). Prior to his leadership of the Cardiovascular Group, Mr. Bergheim was the President of Immunotherapy Worldwide, the President of BioTech Europe, and the President of Baxter Germany. After leaving Baxter, Mr. Bergheim became a General Partner at the venture capital firm Domain Associates, LLC. During his tenure at Domain, Mr. Bergheim participated in forming several companies including Volcano Corporation and Glaukos Corporation. In 2005, he founded and continues to be principal partner of Fjord Ventures, a Southern California – based investment and management group developing emerging lifescience companies.
LONE STAR HEART Frank Ahmann
With more than 25 years of experience in the biotech and medical device industries, Mr. Ahmann has held executive management positions ranging from operations management to new product development and sales and marketing. Mr. Ahmann was involved with the foundation and development of start-ups such as Chimeric Therapies, Inc., Nephrogenex, Inc., Allvivo, Inc., and -13
Corporate Access Event January 11 - 14, 2016
CardioPolymers, Inc. The latter was acquired recently by LoneStar Heart. He has also been a strategy consultant to various biotechnology start-up ventures and venture capital firms in the cardiovascular, oncology, and stem cell therapy sectors. Previously, Mr. Ahmann spent 10 years in management positions in Europe and North America at Baxter International’s Biotech Group and Cardiovascular Group (now Edwards LifeSciences). Among many products, he launched the first comprehensive system for the collection, processing, storage, and administration of hematopoietic stem cells. A German citizen who grew up in Mexico, Mr. Ahmann is a native Spanish, German, and English speaker with strong ties to the European medical market. Mr. Ahmann holds a BBA with Honors from the University of Texas at Austin and an MBA from Columbia University Graduate School of Business in New York City.
SPHERA FUNDS MANAGEMENT, LTD Hagai Schor 212-946-3563
Mr. Schor is the head of scientific research and a senior scientific analyst at Sphera Funds. Before joining Sphera in 2007, he was vice president at Rosseta Genomics. Prior to that, he spent five years at Teva in business development and new project development. He earned his MBA from the Kellogg School of Business at Northwestern University and a master’s and Ph.D. from the Weizmann Institute of Science.
Sphera Funds Management ("Sphera") is an Israeli-based fund manager established in 2004. Sphera and its affiliated entities are managing three separate hedge funds: Sphera Fund - a long/short equity fund focused on Israeli and Israeli related equities, Sphera Global Healthcare Fund - a long/short healthcare equity fund focused on the global pharma and biotech sectors, and Sphera Small Cap Fund - a long/short equity fund focused on small-cap Israeli equities. Sphera Fund invests primarily in a range of long/short equities of Israeli companies traded in Israel, US and European markets.
RIDGEBACK CAPITAL MANAGEMENT, LLC Matt Mezvinsky, Analyst 212-624-2600 [email protected]
Mezvinsky is an analyst at Ridgeback Capital Management, LLC. He joined the firm in September 2005. Previously, Mezvinsky was an analyst at Banc of America Securities (June 2003 - August 2005). He received a BS in Finance from Wharton School at the University of Pennsylvania ('03).
Ridgeback Capital Management, LLC invests in U.S. healthcare stocks across all market capitalizations. The firm employs a long/short strategy.
-14
Corporate Access Event January 11 - 14, 2016
Top 10 Holdings (USD, mm) Company Value Value Change % Port Genfit SA 34.47 0.00 32.85% Applied Genetic Technologies Corp. 28.69 0.00 27.34% Cara Therapeutics, Inc. 25.65 0.00 24.44% OncoSec Medical, Inc. 6.55 0.00 6.25% Trillium Therapeutics Inc. 5.55 0.00 5.29% MediGene AG 4.03 -0.75 3.84%
JUVENTAS THERAPEUTICS Rahul Aras, Ph.D.
Rahul Aras, Ph.D. is the founding CEO for Juventas Therapeutics. Dr. Aras has led the Company since its inception in 2007 and has leveraged his scientific research and business experience to lead Juventas towards commercialization of its innovative therapies. Dr. Aras has successfully transitioned Juventas’ technologies from the laboratory into mid-stage clinical trials. Prior to leading Juventas, Dr. Aras was the Director of Life Science Commercialization at Cleveland Clinic Innovations where he managed commercialization of all biotechnology and pharmaceutical related technologies developed at Cleveland Clinic. Dr. Aras has held research positions at Vanderbilt University Medical Center and Massachusetts General Hospital and has published articles in several leading scientific journals. He received a B.S. from Tufts University and a Ph.D. in biomedical research from New York University.
Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating from the laboratory of cofounder Marc Penn, M.D., Ph.D., FACC and the technologies he discovered and developed at the Cleveland Clinic. Juventas is currently initiating a Phase 2b study in advanced peripheral artery disease.
WELLS FARGO SECURITIES Marisa Hehman Frackman Ms. Frackman is director healthcare equity capital markets at Wells Fargo. Prior to joining WF in 2007, she was healthcare investment banking analyst with Wachovia Securities and before that, at Deutsche Bank. She holds a degree in finance from Georgetown University.
Wells Fargo Securities delivers a comprehensive set of capital markets products and services to customers, including originating and distributing public debt and equity, hedging interest rates, commodity and equity risks, advising on mergers and acquisitions, and originating structured lending
-15
Corporate Access Event January 11 - 14, 2016
facilities and municipal bonds. The institutional broker dealer is comprised of more than 4000 team members in 40+ offices across the United States, Europe and Asia.
RS INVESTMENT MANAGEMENT COMPANY, LLC Christopher “Chris” Clark, CFA, Portfolio Manager 415-591-2706 [email protected]
Clark is an analyst and a portfolio manager on the growth team at RS Investment Management Company, LLC. He joined the firm in May 2007. Previously, Clark was an analyst at TIAA-CREF Investment Management (January 2004 - May 2007). Prior to that, he was a research assistant at Dresdner RCM Global Investors (June 2001 - December 2003). Clark received a BA in Economics from the University of Virginia ('00). He prefers to initiate outside contact.
RS Investment Management Company, LLC invests in U.S. stocks across small- through mega-cap. The firm is primarily a growth, core growth, and value investor, and also utilizes industry/region specific strategies such as U.S. technology, global natural resources, the S&P 500, emerging markets, and greater China. For all portfolios, RS Investments seeks stocks with: (a) solid business plans; (b) quality management; (c) unique products and services; and, (d) above-average earnings and revenue growth. The firm considers selling a stock when: (a) target prices are reached; (b) prices decline 15%; (c) growth rates slow; (d) strategic direction of management changes; or, (e) there is a more attractive opportunity.
Top 10 Holdings (USD, mm) Company Value Value Change % Port LogMeIn, Inc. 201.90 27.53 1.76% Euronet Worldwide, Inc. 193.05 32.96 1.68% Liberty Interactive Corporation 175.56 48.54 1.53% Liberty Interactive Corporation 159.71 -16.55 1.39% Pinnacle Foods Inc. 142.68 30.46 1.24% Ritchie Bros. Auctioneers, Inc. 134.54 50.69 1.17% CommVault Systems, Inc. 129.44 28.50 1.13% Restoration Hardware Holdings, Inc. 123.08 37.77 1.07% Equity Commonwealth 118.86 30.28 1.04% Ligand Pharmaceuticals, Inc. 118.13 33.94 1.03%
CHARDAN CAPITAL MARKETS, LLC Gbolahan “Gbola” Amusa, CFA 646-465-9024 [email protected]
-16
Corporate Access Event January 11 - 14, 2016
Amuse is an analyst and a managing director at Chardan Capital Markets, LLC (Research). He earned a BSE with Honors in Biomedical Engineering from Duke University, a Doctor of Medicine (MD) from Washington University Medical School, and an MBA in Finance and Economics from Booth School of Business at the University of Chicago.
Stocks Covered AAVL, AGTC, AXON, ESPR, FOLD, IMNP, LBIO, LJPC, OHRP, OPHT, QURE, REGN, TIG, VSTA
Chardan Capital Markets, LLC (Research) writes research on U.S. stocks across all market capitalizations and sectors such as: (a) agriculture chemicals (b) television broadcasting; (c) medical instruments and supplies; (d) technology services; (e) wireless communications; (f) telecommunication services; (g) semiconductors; and, (h) software.
GREAT POINT PARTNERS, LLC Brett Erkman 203-971-3300 [email protected]
Erkman is a principal and research associate at Great Point Partners, LLC. He joined the firm In October 2006. Previously, Erkman was an associate at ThinkEquity Partners, LLC (December 2005 - September 2006). Prior to that, he was a senior financial analyst at Abbott Laboratories (April 2000 - December 2005). Erkman received a BS in Finance from DePaul University ('04).
Great Point Partners, LLC primarily invests in Healthcare and Industrials sector across U.S. region with all market caps. The firm is an alternative investor. Great Point Partners, LLC employs a long/short investment strategy, using a bottom up approach. The firm invest in PIPEs (Private Investments in Public Entity) and other directly negotiated investments.
Top 10 Holdings (USD, mm) Value Company Value % Port Change Vanda Pharmaceuticals Inc. 19.35 3.40 7.98% Five Prime Therapeutics, Inc. 18.88 8.44 7.79% Connecture, Inc. 18.82 0.00 7.76% Adamas Pharmaceuticals Inc. 18.58 5.65 7.66% Zogenix, Inc. 18.40 14.18 7.59% Tetraphase Pharmaceuticals, Inc. 16.09 6.21 6.64% Dyax Corp. 14.32 5.29 5.90% Relypsa, Inc. 14.24 9.79 5.87% Exelixis, Inc. 8.92 8.92 3.68% Paratek Pharmaceuticals, Inc 8.62 0.73 3.56%
-17
Corporate Access Event January 11 - 14, 2016
# # #
-18